Down-regulation by resveratrol of basic fibroblast growth factor-stimulated osteoprotegerin synthesis through suppression of Akt in osteoblasts

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 17886-17900

  Kuroyanagi, Gen ^a,b   Otsuka, Takanobu ^a   Yamamoto, Naohiro ^a,b   Matsushima Nishiwaki, Rie ^b   Nakakami, Akira ^b   Mizutani, Jun ^a   Kozawa, Osamu ^b   Tokuda, Haruhiko ^b,c  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Fibroblast growth factor (FGF 2); Osteoblast; Osteoprotegerin; Resveratrol

Indexed keywords

ALCOHOL; LACTATE DEHYDROGENASE; OSTEOPROTEGERIN; RESVERATROL; SODIUM CHLORIDE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; FLAVONOID; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE B; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; STILBENE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CHEMICAL STRESS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ASSAY; FLOW CYTOMETRY; HEAT STRESS; IN VITRO STUDY; MECHANICAL STRESS; NERVE CELL NECROSIS; NERVE SURGERY; NEUROPROTECTION; NONHUMAN; OSMOTIC STRESS; OSTEOBLAST; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VESTIBULAR SCHWANNOMA SURGERY; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PHOSPHORYLATION;

3T3 CELLS; ANIMALS; ANTHRACENES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOWN-REGULATION; FIBROBLAST GROWTH FACTOR 2; FLAVONOIDS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOBLASTS; OSTEOPROTEGERIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RECOMBINANT PROTEINS; STILBENES;

EID: 84907841512     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151017886     Document Type: Article

References (44)

1. Karsenty, G.; Wagner, E. F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell. 2002, 2, 389-406.
2. Parfit, A. M. Targeted and nontargeted bone remodeling: Relationship to basic multicellular unit origination and progression. Bone 2002, 30, 5-7.
3. Simonet, W. S.; Lacey, D. L.; Dunstan, C. R.; Kelley, M; Chang, M. S.; Lüthy, R.; Nguyen, H. Q.; Wooden, S.; Bennett, L.; Boone, T.; et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997, 89, 309-319.
4. Mizuno, A.; Amizuka, N.; Irie, K.; Murakami, A.; Fujise, N.; Kanno, T.; Sato, Y.; Nakagawa, N.; Yasuda, H.; Mochizuki, S.; et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247, 610-615.
5. Kwan, T. S.; Padrines, M.; Théoleyre, S.; Heymann, D.; Fortun, Y. IL-6, RANKL, TNF-α/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004, 15, 49-60.
6. Baylink, D. J.; Finkleman, R. D.; Mohan, S. Growth factor to stimulate bone formation. J. Bone Miner. Res. 1993, 8, 565-572.
7. Hurley, M. M.; Abreu, C.; Harrison, J. R.; Lichtler, A. C.; Raisz, L. G.; Kream, B. E. Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 1993, 268, 5588-5593.
8. Aguirre, J. I.; Leal, M. E.; Rivera, M. F.; Vanegas, S. M.; Jorgensen, M.; Wronski, T. J. Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats. J. Bone Miner. Res. 2007, 22, 877-888.
9. Bolander, M. E. Regulation of fracture repair by growth factors. Proc. Soc. Exp. Biol. Med. 1992, 200, 165-170.
10. Marie, P. J. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 2003, 316, 23-32.
11. Tokuda, H.; Kozawa, O.; Uematsu, T. Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: Divergent regulation by p44/p42 mitogen-activated protein kinase and p38 mitogenactivated protein kinase. J. Bone Miner. Res. 2003, 15, 2371-2379.
12. Tokuda, H.; Hirade, K.; Wang, X.; Oiso, Y.; Kozawa, O. Involvement of SAPK/JNK in basic fibroblast growth factor-induced VEGF release in osteoblasts. J. Endocrinol. 2003, 177, 101-107.
13. Kozawa, O.; Tokuda, H.; Matsuno, H.; Uematsu, T. Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts. J. Cell. Biochem. 1999, 74, 479-485.
14. Chan, T. O.; Rittenhouse, S. E.; Tsichlis, P. N. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositidedependent phosphorylation. Annu. Rev. Biochem. 1999, 68, 965-1014.
15. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 2002, 296, 1655-1657.
16. Chaudhary, L. R.; Hruska, K. A. The cell survival signal Akt is differently activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J. Cell. Biochem. 2001, 81, 304-311.
17. Debiais, F.; Lefevre, G.; Lemonnier, J.; Le Mee, S.; Lasmoles, F. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent-β-catenin-independent signaling pathway. Exp. Cell Res. 2004, 297, 235-246.
18. Takai, S.; Tokuda, H.; Hanai, Y.; Kozawa, O. Activation of phosphatidylinositol 3-kinase/Akt limits FGF-2-induced VEGF release in osteoblasts. Mol. Cell. Endcrinol. 2007, 267, 46-54.
19. Jankun, J.; Selman, S. H.; Wiercz, R. S.; Skrzypczak-Jankun, E. Why drinking green tea could prevent cancer. Nature 1997, 387, 561.
20. Harbourne, J. B.; Williams, C. A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55, 481-504.
21. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73, 417-435.
22. Koo, S. H.; Montminy, M. In vino veritas: A tale of two Sirt1s? Cell 2006, 127, 1091-1093.
23. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339, 1523-1526.
24. Kubo, J. T.; Stefanick, M. L.; Robbins, J.; Wactawski-Wende, J.; Cullen, M. R.; Freiberg, M.; Desai, M. Preference for wine is associated with lower hip fracture incidence in post-menopausal women. BMC Womens Health 2013, 13, 36.
25. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Allard, V. V.; Prabhu, J. S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337-342.
26. Milne, J. C.; Lambert, P. D.; Schenk, S.; Carney, D. P.; Smith, J. J.; Gagne, D. J.; Jin, L.; Boss, O.; Perni, R. B.; Vu, C. B.; et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712-716.
27. Alessi, D. R.; Cuenda, A.; Cohen, P.; Dudley, D. T.; Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 1995, 270, 27489-27494.
28. Cuenda, A.; Rouse, J.; Doza, Y. N.; Meier, R.; Cohen, P.; Gallagher, T. F.; Young, P. R.; Lee, J. C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364, 229-233.
29. Bennett, B. L.; Sasaki, D. T.; Murray, B. W.; O'Leary, E. C.; Sakata, S. T.; Xu, W.; Leisten, J. C.; Motiwala, A.; Pierce, S.; Satoh, Y.; et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Gene 2001, 98, 13681-13686.
30. Hu, Y.; Qiao, L.; Wang, S.; Rong, S. B.; Meuillet, E. J.; Berggren, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J. Med. Chem. 2000, 43, 3045-3051.
31. Nakagawa, N.; Yasuda, H.; Yano, K.; Mochizuki, Si.; Kobayashi, N.; Fujimoto, H.; Shima, N.; Morinaga, T.; Chikazu, D.; Kawaguchi, H.; et al. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 1999, 265, 158-163.
32. Boily, G.; He, X. H.; Pearce, B.; Jardine, K.; McBurney, M. W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 2009, 28, 2882-2893.
33. Guarente, L.; Picard, F. Calorie restriction-the SIR2 connection. Cell 2005, 120, 473-482.
34. Kyriakis, J. M.; Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81, 807-869.
35. Widmann, C.; Gibson, S.; Jarpe, M. B.; Johnson, G. L. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79, 143-180.
36. Kuroyanagi, G.; Mizutani, J.; Kondo, A.; Yamamoto, N.; Matsushima-Nishiwaki, R.; Otsuka, T.; Kozawa, O.; Tokuda, H. Suppression by resveratrol of prostaglandin D2-stimulated osteoprotegerin synthesis in osteoblasts. Prostaglandins Leukot. Essent. Fatty Acids 2014, 91, 73-80.
37. Kuroyanagi, G.; Tokuda, H.; Matsushima-Nishiwaki, R.; Kondo, A.; Mizutani, J.; Kozawa, O.; Otsuka, T. Resveratrol suppresses prostaglandin F2α-induced osteoprotegerin synthesis in osteoblasts: Inhibition of the MAP kinase signaling. Arch. Biochem. Biophys. 2014, 542, 39-45.
38. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Prostanoid receptors: Structures, properties, and functions. Physiol. Rev. 1999, 79, 1193-1226.
39. Eswarakumar, V. P.; Lax, I.; Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16, 139-149.
40. Pillai, V. B.; Sundaresan, N. R.; Gupta, M. P. Regulation of Akt signaling by sirtuins: Its implication in cardiac hypertrophy and aging. Circ. Res. 2014, 114, 368-378.
41. Sudo, H.; Kodama, H.; Amagai, Y.; Yamamoto, S.; Kasai, S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 1983, 96, 191-198.
42. Kozawa, O.; Tokuda, H.; Miwa, M.; Kotoyori, J.; Oiso, Y. Cross-talk regulation between cyclic AMP production and phosphoinositide hydrolysis induced by prostaglandin E2 in osteoblast-like cells. Exp. Cell Res. 1992, 198, 130-134.
43. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
44. Kato, K.; Ito, H.; Hasegawa, K.; Inaguma, Y.; Kozawa, O.; Asano, T. Modulation of the stress-induced synthesis of hsp27 and αB-crystallin by cyclic AMP in C6 rat glioma cells. J. Neurochem. 1996, 66, 946-950.